Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

2.4K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.4K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.8K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

2.5K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical application of <sup>1</sup>H MRS in the human brain at 7T.

Frontiers in neuroscience·2026
Same author

Cardiogenic Shock and Symmetrical Peripheral Gangrene in Relapsed Follicular Lymphoma: A Case Report With Bordetella bronchiseptica Co-infection.

Cureus·2026
Same author

Performance of traumatic encephalopathy syndrome criteria in identifying individuals with chronic traumatic encephalopathy.

Nature medicine·2026
Same author

Chronic traumatic encephalopathy neuropathologic change is associated with highest stage limbic-predominant age-related TDP-43 encephalopathy.

Journal of neuropathology and experimental neurology·2026
Same author

Neoantigens and stochastic fluctuations regulate T cell proliferation in primary and metastatic malignant brain tumours.

Journal of the Royal Society, Interface·2026
Same author

Disseminated Fungal Infection in Profoundly Immunocompromised Hosts: A Three-Case Series.

Cureus·2026

Related Experiment Video

Updated: Apr 16, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.9K

The progressive myoclonic epilepsies.

Naveed Malek1, William Stewart2, John Greene1

  • 1Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK.

Practical Neurology
|February 28, 2015
PubMed
Summary

Progressive myoclonic epilepsies (PMEs) are severe neurological disorders with poor prognosis and treatment resistance. Early diagnosis through specific investigations is crucial for understanding and managing these rare genetic conditions.

Keywords:
EPILEPSYMYOCLONUS

More Related Videos

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

1.9K
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

21.4K

Related Experiment Videos

Last Updated: Apr 16, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.9K
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

1.9K
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

21.4K

Area of Science:

  • Neurology
  • Genetics
  • Rare Diseases

Background:

  • Progressive myoclonic epilepsies (PMEs) are a group of rare, inherited neurological disorders.
  • Characterized by relentless progression, intractable epilepsy, and poor prognosis.
  • Encompasses diverse conditions like Lafora body disease and Gaucher's disease.

Purpose of the Study:

  • To discuss the clinical phenotypes of various PMEs.
  • To summarize diagnostic investigations for identifying the underlying causes.
  • To aid in patient and family understanding of these incurable conditions.

Main Methods:

  • Phenotypic description of PME disorders.
  • Review of diagnostic investigations.
  • Summary of genetic and biochemical testing.

Main Results:

  • PMEs present with diverse phenotypes but share progressive neurological decline.
  • Epilepsy is often treatment-resistant.
  • Genetic and specific biochemical tests are key to diagnosis.

Conclusions:

  • Accurate diagnosis of PMEs is essential for patient management and genetic counseling.
  • Understanding phenotypes and utilizing specific investigations aids in identifying the cause.
  • Despite being incurable, diagnosis provides crucial information for families.